What are the recommended tofacitinib dosing regimens for adults with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, and how should the dose be adjusted in renal impairment?

Tofacitinib Dosing Recommendations

For rheumatoid arthritis and psoriatic arthritis, use tofacitinib 5 mg twice daily; for ulcerative colitis, use 10 mg twice daily for 8 weeks induction followed by 5 mg twice daily maintenance, with dose adjustments required for moderate-to-severe renal impairment (5 mg once daily) and when using potent CYP3A4 inhibitors (5 mg once daily). 1, 2

Standard Dosing by Indication

Rheumatoid Arthritis and Psoriatic Arthritis

• Standard dose: 5 mg twice daily 1, 2
• Alternative: 11 mg extended-release once daily 1
• This dose provides consistent efficacy with a manageable safety profile 3

Ulcerative Colitis

• Induction: 10 mg twice daily for 8 weeks 4, 5

  • In patients with modest response at 8 weeks, consider extending high-dose induction to 16 weeks total 4, 6
  • Extended induction (16 weeks) shows significantly higher clinical response rates (69% vs 45% at week 16) compared to standard 8-week induction 6

• Maintenance: 5 mg twice daily for most patients 4, 5

  • Higher dose (10 mg twice daily) may be considered in patients who lose response on 5 mg twice daily, but only after careful risk-benefit assessment 4
  • Critical safety concern: The 10 mg twice daily maintenance dose is associated with increased risk of pulmonary embolism and all-cause mortality 4
  • FDA recommends tofacitinib use only after failure of or intolerance to TNF antagonists 4

Psoriasis (Off-Label)

• Dosing: 5 mg or 10 mg twice daily 7
• The 10 mg twice daily dose shows greater efficacy but carries higher risk of infections and cytopenia 7
• Not FDA-approved for this indication 7

Dose Adjustments for Renal Impairment

Moderate-to-severe renal impairment (CrCl 30-60 mL/min or CrCl <30 mL/min): Reduce to 5 mg once daily 7, 1, 2

End-stage renal disease on hemodialysis: 5 mg once daily 1, 2

• Tofacitinib AUC increases approximately 40% in ESRD patients on hemodialysis 2
• This reflects the 30% contribution of renal clearance to total tofacitinib elimination 2

Baricitinib note: Not recommended if CrCl <30 mL/min; use 2 mg daily if CrCl 30-60 mL/min 1

Dose Adjustments for Hepatic Impairment

Moderate hepatic impairment: Reduce to 5 mg once daily 7

Severe hepatic impairment (Child-Pugh C): Not recommended 7, 1

Tofacitinib undergoes approximately 70% hepatic metabolism via CYP3A4 2

Drug Interaction Dose Adjustments

Potent CYP3A4 inhibitors (e.g., ketoconazole): Reduce to 5 mg once daily 7, 2

Combined moderate CYP3A4 and potent CYP2C19 inhibition (e.g., fluconazole): Reduce to 5 mg once daily 7

CYP3A4 inducers (e.g., rifampicin for TB treatment): Consider dose increase for tofacitinib and upadacitinib 1

Laboratory Monitoring Thresholds

Do Not Initiate Tofacitinib If:

• Lymphocyte count <500 cells/mm³ 7
• Absolute neutrophil count (ANC) <1000 cells/mm³ 7
• Hemoglobin <9 g/dL 7

Discontinue or Hold Tofacitinib If:

• Lymphocyte count <500 cells/mm³ (confirmed by repeat testing) 7
• ANC <500 cells/mm³ (confirmed by repeat testing) 7
• For persistent ANC <1000 cells/mm³, hold until ANC ≥1000 cells/mm³ 7
• Hemoglobin decreases ≥2 g/dL or is <8.0 g/dL (confirmed by repeat testing) 7

Special Populations and Considerations

Age and Cardiovascular Risk

• In RA patients >65 years with cardiovascular risk factors, tofacitinib shows higher rates of serious infections compared to TNF inhibitors 1
• According to EMA, use in these patients only if no alternative exists 1
• The 10 mg twice daily dose carries several-fold higher infection risk in elderly compared to 5 mg twice daily 1

Ulcerative Colitis Dose De-escalation

• Approximately 29% of UC patients de-escalated from 10 mg to 5 mg twice daily require dose re-escalation 5
• Only 63% recapture response after dose increase 5
• Patients in deep endoscopic remission without prior TNF inhibitor failure are better candidates for dose reduction 8
• Endoscopic subscore should guide dose reduction decisions 8

Comedication

• Can be used with methotrexate 7
• Do not combine with potent immunosuppressants (azathioprine, cyclosporine) or biologics 7
• Avoid during active serious infections 7
• Avoid live vaccines 7

Key Safety Warnings

Herpes zoster prophylaxis: Consider Shingrix vaccination before initiating tofacitinib 7

• Herpes zoster is the most common adverse event of special interest (6% of patients in real-world data) 6

Cardiovascular and thrombotic risk: The 10 mg twice daily dose in UC maintenance is associated with increased pulmonary embolism and mortality risk 4

Infection risk: Higher doses (10 mg twice daily) carry substantially increased serious infection rates, particularly in elderly patients 1